News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi H, I think I prefer "Rummer." 
pirate@hiccough.arrg
|
Followers
|
4
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
347
|
|
Created
|
10/02/00
|
Type
|
Free
|
| Moderators | |||
Outstanding Shares: 39,709,015 Shares.
Authorized Shares: 200,000,000 Shares.
Number Of Shareholders: 870.
Company Status: In CH11 process, no liquidation value.
Important Websites
Home Page: http://www.biopure.com/
Investor Kit: http://www.biopure.com/corporate/reports/bpur_ekit.zip
Corporate Contact
Biopure Corporation
11 Hurley Street
Cambridge, MA 02141
Phone 617-234-6500
Fax 617-234-6505
About Biopure Corporation (Nasdaq: BPUR)
Biopure Corporation develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. Using our patented and proprietary technology, we have developed and manufacture two products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use, and Oxyglobin® (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use. Hemopure is being sold in South Africa for the treatment of adult surgical patients who are acutely anemic and for eliminating, reducing or delaying the need for allogenic red blood cell transfusion in these patients. A marketing authorization application for Hemopure is pending in the United Kingdom, also for a surgery indication.
We have been developing Hemopure for the treatment of patients with cardiovascular ischemia and supporting the U.S. Navy's government-funded development of the product for out-of-hospital treatment of trauma patients in hemorrhagic shock. To exploit the body of preclinical and clinical information we have involving anemia, we are now beginning development for use of Hemopure in anemic cancer patients and end-of-life patients.
Oxyglobin, our veterinary product for the treatment of anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission. We have sold approximately 200,000 units of Oxyglobin.
We are headquartered and operate a cGMP manufacturing facility in Cambridge, Massachusetts.
Products
Oxygen Bridge
The purpose of intravenous oxygen-delivery support is to help stabilize the patient and prevent tissue damage or organ dysfunction associated with oxygen deprivation. When Hemopure or Oxyglobin is infused into the bloodstream, its chemically stabilized hemoglobin molecules both carry oxygen in the plasma (the fluid part of blood) and facilitate the release of oxygen from red blood cells, thereby increasing diffusion of oxygen to tissues. If necessary, this effect can be extended over time by repeat dosing to provide a continuous Oxygen Bridge until anemic or ischemic patients receive other appropriate therapy.
Hemopure South Africa
HBOC-201 [hemoglobin glutamer - 250 (bovine)]
Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)], is a first-in-class product for human use and approved in South Africa for the treatment of acutely anemic adult surgical patients. Its purpose is to eliminate, reduce or delay these patients' need for allogenic red blood cell transfusions.
Current list: http://www.biopure.com/technology_and_products.php
Biopure Corporation Management
Zafiris G. Zafirelis
Chairman, President and Chief Executive Officer
Zafiris G. Zafirelis has been President, Chief Executive Officer and a director of Biopure since June 2004. In January 2006 he was appointed Chairman of the Board. Before coming to Biopure, he was CEO and a director of MedQuest Product, Inc, Salt Lake City, UT, a pioneering developer of implantable ventricular assist devices. He previously served as CEO and a director of CardiacAssist, Inc., Pittsburgh, PA, and, for four years prior to Biopure's initial public offering, as Director of Product Applications at Biopure. He holds a graduate diploma in chemistry from the University of Rhodesia and an M.B.A. from the University of Southern California.
David A. Butler
Interim Chief Financial Officer
Mr. Butler most recently served as Vice President, Finance and Administration at the Millard Group, Inc., a services & consulting company. Prior to that position, he served as Vice President, Finance, Chief Financial Officer and Treasurer at Circe Biomedical, Inc., a development-stage medical device manufacturer, formerly in Lexington, Mass.
Jane Kober
Senior Vice President, General Counsel and Secretary
Jane Kober has been Senior Vice President, General Counsel and Secretary of Biopure since 1998. From June 1989 to April 1998, she was a partner in LeBoeuf, Lamb, Greene & MacRae, L.L.P. Ms. Kober holds a J.D. degree from Case Western Reserve University, an M.A. degree from the University of Chicago and a B.A. in English from the Pennsylvania State University. She serves as a director of HTV Industries, Inc.
Geoffrey J. Filbey
Vice President, Engineering
Geoffrey J. Filbey joined Biopure in 1985 and has served as Vice President, Engineering since 1995. He previously worked at Stone & Webster Engineering Corporation for 14 years as a project manager and process engineer. Prior to Stone & Webster, he was a plant manager for eight years at Morganite Carbon Co. in London. Mr. Filbey holds a B.Sc. degree in engineering from the City University in London, England.
A. Gerson Greenburg
Vice President, Medical Affairs
A. Gerson Greenburg, M.D., Ph.D. joined Biopure as Vice President, Medical Affairs, in May 2006. He is a board-certified general surgeon and expert in oxygen therapeutics with over 40 years of experience in clinical care, quality systems, teaching and research. A professor emeritus of surgery at Brown University School of Medicine in Providence, R.I., Dr. Greenburg retired from The Miriam Hospital in April 2006 after serving as chief of clinical quality management since 2003 and as surgeon-in-chief from 1986 to 2005. In 2005, he received the hospital's Charles C.J. Carpenter Outstanding Physician of the Year Award. Previously, he was chief of general surgery and surgical intensive care at the Veterans Administration Medical Center in San Diego, Calif., and was a professor of surgery at the University of California, San Diego.
W. Richard Light
Vice President, Technology Development
W. Richard Light, Ph.D., rejoined Biopure as Vice President, Technology Development, in February 2005. During the previous year, Dr. Light was Vice President, Development, at Aeris Therapeutics in Woburn, Mass. He originally joined Biopure in 1990 and has held several positions, including Vice President, Process Technology; Director, Product Development; and Associate Director, Analytical and Protein Chemistry. Dr. Light previously served as a research biochemist and postdoctoral fellow at the Naval Research Laboratory in Washington, D.C. He holds a Ph.D. in biochemistry from Rice University, and has a B.S. in biology and a B.A. in chemistry from Washington & Lee University.
Virginia T. Rentko
Vice President, Preclinical Development
Virginia T. Rentko, V.M.D. is Vice President, Preclinical Development, at Biopure. She is board certified in internal medicine and is an adjunct clinical assistant professor in the Department of Clinical Sciences at Tufts University School of Veterinary Medicine. Dr. Rentko received her V.M.D. degree from the University of Pennsylvania and completed clinical training at the University of Pennsylvania and Tufts University. She obtained her M.S. degree in Zoology at the Ohio State University and her B.S. degree in Biology at Boston University. She is a diplomate of the American College of Veterinary Internal Medicine, and is an active member of the Association of Veterinary Hematology and Transfusion Medicine and the American Veterinary Medical Association.
Barry L. Scott
Vice President, Business Development
Barry L. Scott has been Vice President, Business Development, since September 2003. He joined the company in June 2002 as Vice President, International Business Development. From 1998 until 2002 Mr. Scott worked for Bristol-Myers Squibb Company, most recently as Vice President, International Business Development, Europe. From 1996 until 1998 he was the general manager of Bristol-Myers Squibb, Ltd., South Africa. He also held several positions, including Director of Marketing and Sales, during his 20 years at Merck Sharp and Dhome, the South Africa subsidiary of Merck & Co. Mr. Scott holds the Diploma in Education from the University of Rhodesia and the Diploma in Marketing Management from the Institute of Marketing Management, South Africa.
Filings and Other Information
http://sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000815508&owner=include&count=40
News
http://investor.biopure.com/phoenix.zhtml?c=114417&p=irol-news&nyo=0
Chart and Stock Information
Share Structure
O/S: 33,918,000
Ref: http://investor.biopure.com/phoenix.zhtml?c=114417&p=IROL-secToc&TOC=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvY29udGVudHMueG1sP2lwYWdlPTU1MzkzMjYmcmVwbz10ZW5r
American Stock Transfer & Trust Co.
Shareholder Services
59 Maiden Lane, Plaza Level
New York, NY 10038
Phone: 800-937-5449
Fax: 718-236-2641
Charts
_______________________________________
Updated 16 MAY 2008 by Soapy Bubbles
